ChromaDex Co. (NASDAQ:CDXC – Get Rating) major shareholder Hoi Shuen Solina Holly Chau acquired 960,000 shares of ChromaDex stock in a transaction that occurred on Friday, September 30th. The stock was acquired at an average price of $1.25 per share, with a total value of $1,200,000.00. Following the completion of the purchase, the insider now directly owns 7,885,641 shares in the company, valued at approximately $9,857,051.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.
ChromaDex Price Performance
CDXC stock traded up $0.06 during mid-day trading on Monday, hitting $1.29. 547 shares of the stock were exchanged, compared to its average volume of 440,557. The business has a fifty day moving average price of $1.55 and a 200 day moving average price of $1.84. ChromaDex Co. has a 12 month low of $1.15 and a 12 month high of $6.98. The stock has a market capitalization of $88.16 million, a price-to-earnings ratio of -3.15 and a beta of 1.71.
Get ChromaDex alerts:ChromaDex (NASDAQ:CDXC – Get Rating) last released its earnings results on Wednesday, August 10th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). ChromaDex had a negative return on equity of 99.51% and a negative net margin of 41.01%. During the same period in the prior year, the company posted ($0.08) earnings per share. As a group, equities analysts forecast that ChromaDex Co. will post -0.3 EPS for the current fiscal year.
Analysts Set New Price Targets
Several equities analysts recently commented on CDXC shares. B. Riley cut ChromaDex from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $6.00 to $2.40 in a research report on Thursday, August 11th. HC Wainwright cut their price objective on ChromaDex from $7.00 to $5.50 and set a "buy" rating for the company in a report on Monday, August 29th. Finally, Oppenheimer downgraded shares of ChromaDex from an "outperform" rating to a "market perform" rating in a research note on Tuesday, August 16th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $5.48.Institutional Investors Weigh In On ChromaDex
Institutional investors have recently made changes to their positions in the business. Tieton Capital Management LLC raised its position in ChromaDex by 242.8% in the 1st quarter. Tieton Capital Management LLC now owns 1,428,742 shares of the company's stock worth $3,515,000 after purchasing an additional 1,012,016 shares during the period. Millennium Management LLC bought a new stake in shares of ChromaDex in the 2nd quarter valued at about $1,275,000. Renaissance Technologies LLC boosted its holdings in ChromaDex by 1,004.0% during the 1st quarter. Renaissance Technologies LLC now owns 420,501 shares of the company's stock valued at $1,034,000 after acquiring an additional 382,413 shares during the period. Vanguard Group Inc. boosted its holdings in ChromaDex by 9.5% during the 1st quarter. Vanguard Group Inc. now owns 2,781,437 shares of the company's stock valued at $6,842,000 after acquiring an additional 240,414 shares during the period. Finally, GSA Capital Partners LLP bought a new position in ChromaDex during the 1st quarter worth approximately $134,000. Hedge funds and other institutional investors own 41.83% of the company's stock.
ChromaDex Company Profile
(Get Rating)
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Featured Articles
- Get a free copy of the StockNews.com research report on ChromaDex (CDXC)
- Near-Term Headwinds Send Nike To The Bargain Basement
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- Is the Bond Market Signaling a Market Bottom?
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.